Hybridization of ALK EML4 fusion probe to a lung adenocarcinoma tissue section showing normal signal pattern (2R2G).


The inversion in 2p21 and 2p23 leading to a fusion of the kinase domain of ALK (anaplastic lymphoma kinase) and EML4 (echinoderm microtubule associated protein like 4) has been described in 5-7% of non-small cell lung cancer (NSCLC) cases. Multiple tyrosine kinsae inhibitors (TKI's) specific for ALK have since been approved for first line treatment of NSCLC-patients carrying the fusion gene ALK-EML4. These ALK inhibitors include crizotinib (Xalkori), alectinib (Alecensa) and ceritinib (Zykadia). The ALK/EML4 t(2;2); inv(2) Fusion probe is designed as a dual-color assay to detect the fusion of the ALK gene with the EML4 gene by paracentric inversion with breakage and reunion occurring at bands 2p21 and 2p23.

Soda et al, Nature, 2007, 448, 561-566.
Koivunen et al, Clin Cancer Res, 2008, 14, 4275-4283.

Recently Viewed